1. Home
  2. SKYE vs VSTA Comparison

SKYE vs VSTA Comparison

Compare SKYE & VSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • VSTA
  • Stock Information
  • Founded
  • SKYE 2012
  • VSTA 1966
  • Country
  • SKYE United States
  • VSTA Brazil
  • Employees
  • SKYE N/A
  • VSTA N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • VSTA Other Consumer Services
  • Sector
  • SKYE Health Care
  • VSTA Real Estate
  • Exchange
  • SKYE Nasdaq
  • VSTA Nasdaq
  • Market Cap
  • SKYE 294.2M
  • VSTA 285.4M
  • IPO Year
  • SKYE N/A
  • VSTA 2020
  • Fundamental
  • Price
  • SKYE $6.44
  • VSTA $3.03
  • Analyst Decision
  • SKYE Strong Buy
  • VSTA Hold
  • Analyst Count
  • SKYE 4
  • VSTA 2
  • Target Price
  • SKYE $19.25
  • VSTA $4.50
  • AVG Volume (30 Days)
  • SKYE 414.1K
  • VSTA 21.9K
  • Earning Date
  • SKYE 01-01-0001
  • VSTA 08-07-2024
  • Dividend Yield
  • SKYE N/A
  • VSTA N/A
  • EPS Growth
  • SKYE N/A
  • VSTA N/A
  • EPS
  • SKYE N/A
  • VSTA N/A
  • Revenue
  • SKYE N/A
  • VSTA $306,988,867.00
  • Revenue This Year
  • SKYE N/A
  • VSTA $15.39
  • Revenue Next Year
  • SKYE N/A
  • VSTA $15.04
  • P/E Ratio
  • SKYE N/A
  • VSTA N/A
  • Revenue Growth
  • SKYE N/A
  • VSTA 20.02
  • 52 Week Low
  • SKYE $1.44
  • VSTA $2.90
  • 52 Week High
  • SKYE $19.41
  • VSTA $4.55
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 36.20
  • VSTA 40.47
  • Support Level
  • SKYE $5.48
  • VSTA $2.96
  • Resistance Level
  • SKYE $6.93
  • VSTA $3.13
  • Average True Range (ATR)
  • SKYE 1.03
  • VSTA 0.14
  • MACD
  • SKYE -0.03
  • VSTA 0.02
  • Stochastic Oscillator
  • SKYE 37.30
  • VSTA 41.67

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

Share on Social Networks: